High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab

• J. Garde-Noguera ^[1] ; M. Gil-Raga ^[2] ; E. Evgenyeva ^[4] ; J. A. García ^[3] ; A. Llombart-Cussac ^[1] ; C. Camps-Herrero ^[3]
  1. [1] Hospital Arnau de Vilanova

     Hospital Arnau de Vilanova

     Valencia, España

     
  2. [2] Hospital de Sagunto

     Hospital de Sagunto

     Sagunto/Sagunt, España

     
  3. [3] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  4. [4] Hospital Marina Salud de Denia, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 4 (April 2016), 2016, págs. 405-412
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To analyse the prognostic role of the immunohistochemical expression of pKDR in patients with advanced colorectal cancer treated with oxaliplatin and fluoropyrimidines combination chemotherapy with or without bevacizumab.

    Methods Retrospective multicentre study, carried out at four hospitals in the Valencian Community (Spain). Patients evolution was compared based on the immunohistochemical expression of pKDR, classified using 4 categories: 0 (undetectable), 1 (mild), 2 (moderate) and 3 (high intensity). Patients were divided into two groups for the analysis: group 1 with low expression (0–1) vs. group 2 with high expression (2–3).

    Results Histological samples for the pKDR analysis were available for 84 of the 112 patients selected. Seven (8.3 %) had undetectable or mild expression of pKDR (Group 1) and 77 (91.7 %) showed moderate or high expression of pKDR (Group 2). Response rate in Group 1 was 100 % compared to 54.2 % in Group 2 (p = 0.019). Progression-free survival (PFS) (15 vs. 12 months, p = 0.4) and overall survival (OS) (28 vs. 22 months, p = 0.09) were numerically but not significantly higher in patients from Group 1 vs. Group 2. Patients from Group 2 who received bevacizumab presented a significantly higher PFS (13 vs. 11, p = 0.015) and a numerically higher OS (23 vs. 17 months, p = 0.27) than those treated exclusively with chemotherapy.

    Conclusions Our results suggest that the absence or low expression of pKDR is associated with a better prognostic profile in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab. Patients with a high pKDR expression benefit from the combination of chemotherapy with bevacizumab.